Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Eijiro, Endo, Makoto, Matsumoto, Yoshihiro, Tsuchihashi, Kenji, Ito, Mamoru, Kusaba, Hitoshi, Nabeshima, Akira, Nawata, Tomoya, Maekawa, Akira, Matsunobu, Tomoya, Setsu, Nokitaka, Fujiwara, Toshifumi, Iida, Keiichiro, Nakagawa, Makoto, Hirose, Takeshi, Kanahori, Masaya, Oyama, Ryunosuke, Isobe, Taichi, Ariyama, Hiroshi, Kohashi, Kenichi, Yamamoto, Hidetaka, Oda, Yoshinao, Iwamoto, Yukihide, Akashi, Koichi, Baba, Eishi, Nakashima, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584915/
https://www.ncbi.nlm.nih.gov/pubmed/34768491
http://dx.doi.org/10.3390/jcm10214972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584915/
https://www.ncbi.nlm.nih.gov/pubmed/34768491
http://dx.doi.org/10.3390/jcm10214972

Ejemplares similares